Max F. Perutz Laboratories, Center for Molecular Biology, Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna Biocenter (VBC), Dr. Bohr-Gasse 9/4, A-1030 Vienna, Austria.
Antibiotics (Basel). 2016 Jun 1;5(2):19. doi: 10.3390/antibiotics5020019.
The bacteriostatic aminoglycoside antibiotic kasugamycin inhibits protein synthesis at an initial step without affecting translation elongation. It binds to the mRNA track of the ribosome and prevents formation of the translation initiation complex on canonical mRNAs. In contrast, translation of leaderless mRNAs continues in the presence of the drug in vivo. Previously, we have shown that kasugamycin treatment in E. coli stimulates the formation of protein-depleted ribosomes that are selective for leaderless mRNAs. Here, we provide evidence that prolonged kasugamycin treatment leads to selective synthesis of specific proteins. Our studies indicate that leaderless and short-leadered mRNAs are generated by different molecular mechanisms including alternative transcription and RNA processing. Moreover, we provide evidence for ribosome heterogeneity in response to kasugamycin treatment by alteration of the modification status of the stalk proteins bL7/L12.
抑菌型氨基糖苷类抗生素井冈霉素在不影响翻译延伸的情况下,在初始步骤抑制蛋白质合成。它与核糖体的 mRNA 轨道结合,阻止规范 mRNA 上翻译起始复合物的形成。相比之下,在体内药物存在的情况下,无 leader 序列的 mRNA 的翻译仍会继续。以前,我们已经表明井冈霉素处理在大肠杆菌中刺激了富含无 leader 序列的 mRNA 的蛋白质耗竭核糖体的形成。在这里,我们提供的证据表明,井冈霉素处理会导致特定蛋白质的选择性合成。我们的研究表明,无 leader 和短 leader 序列的 mRNA 是通过不同的分子机制产生的,包括转录和 RNA 加工的选择。此外,我们通过改变茎蛋白 bL7/L12 的修饰状态,提供了井冈霉素处理引起核糖体异质性的证据。